Viridian Therapeutics, Inc.DE (VRDN) stock
VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30255% above fair value
$30.12+0.06 (+0.20%)
Close on Nov 18, 2026Market cap $3.41BP/E –Yield –
Viridian Therapeutics, Inc.DE cash
Cash and short-term investments held at the end of each period.
Viridian Therapeutics, Inc.DE's cash was $981.50M at Jun 30, 2026. For fiscal 2025 it was $874.70M, up 21.9% from the year before. Over ten years it grew 45.0% a year on average. The highest annual figure on record is $874.70M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $874.70M | +21.9% |
| FY2024 | Dec 31, 2024 | $717.60M | +50.3% |
| FY2023 | Dec 31, 2023 | $477.40M | +12.4% |
| FY2022 | Dec 31, 2022 | $424.60M | +115.5% |
| FY2021 | Dec 31, 2021 | $197.00M | +54.4% |
| FY2020 | Dec 31, 2020 | $127.60M | +376.1% |
| FY2019 | Dec 31, 2019 | $26.80M | -57.1% |
| FY2018 | Dec 31, 2018 | $62.48M | +31.7% |
| FY2017 | Dec 31, 2017 | $47.44M | +114.6% |
| FY2016 | Dec 31, 2016 | $22.10M | +4.1% |
| FY2015 | Dec 31, 2015 | $21.24M | +314.8% |
| FY2014 | Dec 31, 2014 | $5.12M | +2349.3% |
| FY2013 | Dec 31, 2013 | $209.00K | +86.6% |
| FY2012 | Dec 31, 2012 | $112.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $981.50M | +74.2% |
| Q1 FY2026 | Mar 31, 2026 | $762.20M | +19.7% |
| Q4 FY2025 | Dec 31, 2025 | $874.70M | +21.9% |
| Q3 FY2025 | Sep 30, 2025 | $490.90M | -34.8% |
| Q2 FY2025 | Jun 30, 2025 | $563.40M | -1.4% |
| Q1 FY2025 | Mar 31, 2025 | $636.60M | +3.8% |
| Q4 FY2024 | Dec 31, 2024 | $717.60M | +50.3% |
| Q3 FY2024 | Sep 30, 2024 | $753.20M | +140.6% |
| Q2 FY2024 | Jun 30, 2024 | $571.40M | +70.9% |
| Q1 FY2024 | Mar 31, 2024 | $613.20M | +64.0% |
| Q4 FY2023 | Dec 31, 2023 | $477.40M | +12.4% |
| Q3 FY2023 | Sep 30, 2023 | $313.00M | -27.4% |
| Q2 FY2023 | Jun 30, 2023 | $334.30M | +107.4% |
| Q1 FY2023 | Mar 31, 2023 | $373.90M | +113.2% |
| Q4 FY2022 | Dec 31, 2022 | $424.60M | +115.5% |
| Q3 FY2022 | Sep 30, 2022 | $431.30M | +101.7% |
| Q2 FY2022 | Jun 30, 2022 | $161.20M | +47.5% |
| Q1 FY2022 | Mar 31, 2022 | $175.40M | +49.8% |
| Q4 FY2021 | Dec 31, 2021 | $197.00M | +54.4% |
| Q3 FY2021 | Sep 30, 2021 | $213.80M | +610.8% |
| Q2 FY2021 | Jun 30, 2021 | $109.30M | +257.2% |
| Q1 FY2021 | Mar 31, 2021 | $117.10M | +224.4% |
| Q4 FY2020 | Dec 31, 2020 | $127.60M | +376.1% |
| Q3 FY2020 | Sep 30, 2020 | $30.08M | -11.0% |
| Q2 FY2020 | Jun 30, 2020 | $30.60M | -30.3% |
| Q1 FY2020 | Mar 31, 2020 | $36.10M | -29.2% |
| Q4 FY2019 | Dec 31, 2019 | $26.80M | -57.1% |
| Q3 FY2019 | Sep 30, 2019 | $33.80M | -52.1% |
| Q2 FY2019 | Jun 30, 2019 | $43.90M | -42.4% |
| Q1 FY2019 | Mar 31, 2019 | $51.00M | -34.7% |
| Q4 FY2018 | Dec 31, 2018 | $62.48M | +31.7% |
| Q3 FY2018 | Sep 30, 2018 | $70.53M | +64.8% |
| Q2 FY2018 | Jun 30, 2018 | $76.26M | +64.6% |
| Q1 FY2018 | Mar 31, 2018 | $78.10M | +68.6% |
| Q4 FY2017 | Dec 31, 2017 | $47.44M | +114.6% |
| Q3 FY2017 | Sep 30, 2017 | $42.81M | +74.0% |
| Q2 FY2017 | Jun 30, 2017 | $46.34M | – |
| Q1 FY2017 | Mar 31, 2017 | $46.34M | – |
| Q4 FY2016 | Dec 31, 2016 | $22.10M | – |
| Q3 FY2016 | Sep 30, 2016 | $24.60M | – |
See a number that looks wrong?